罗格列酮对2型糖尿病患者血脂及内脂素的影响

目的: 观察罗格列酮对2型糖尿病(T2DM)患者血脂及内脂素(Visfatin)的影响,分析临床治疗效果。方法: 收集本院内分泌科2010年1月-2012年1月收治的T2DM患者84例,随机均分为对照组和罗格列酮治疗组。比较治疗前后空腹血糖(Fasting plasma glucose, FPG)、Hbalc、TC、TG、低密度脂蛋白 (Low density lipoprotein, LDL)、高密度脂蛋白(High density lipoprotein, HDL)、内脂素等生化指标变化情况。结果: 治疗前两组FPG、Hbalc、TC、TG、LDL、HDL和内脂素的表达无统计学差异(P>0.05)。治疗后两组FPG和Hbalc的表达水平均显著减低(P<0.05, P<0.01),罗格列酮组FPG和Hbalc减低幅度显著高于对照组(P<0.05)。对照组治疗前后TC、TG、LDL、HDL和内脂素的表达差异无统计学意义(P>0.05),罗格列酮组治疗后TC、TG、LDL和内脂素表达明显低于治疗前(P<0.05, P<0.01),HDL明显高于治疗前(P<0.05)。罗格列酮组临床治疗有效率(95.2%)明显高于对照组(P<0.05)。罗格列酮组不良反应发生率(23.8%)与对照组(21.4%)比较无统计学差异(P>0.05)。结论: 罗格列酮具有高效的降血糖作用,可以显著降低T2DM患者的血脂和内脂素水平,临床疗效显著,不良反应率低,建议在临床推广应用。

Effects of rosiglitazone on lipid and visfatin in patients with type 2 diabetes mellitus

AIM: To investigate the effects of rosiglitazone on lipid and visfatin in patients with type 2 diabetes mellitus (T2DM) and analysis its clinical efficacy.METHODS: A total of 84 patients with T2DM were enrolled in this study. All cases were divided into control group (n=42) and rosiglitazone treatment group (n=42). Before and after the treatment, FPG, Hbalc, TC, TG, LDL, HDL, visfatin and other biochemical indicators were compared.RESULTS: Before treatment, FPG, Hbalc, TC, TG, LDL , HDL and visfatin had no significant difference between the two groups (P>0.05). After treatment, FPG and Hbalc expression level were significantly reduce (P<0.05, P<0.01), the rosiglitazone group FPG and Hbalc reduce amplitude were significantly higher than that control group (P<0.05). Before and after treatment, treatment group TC, TG, LDL, HDL and visfatin expression difference was not statistically significant (P>0.05), the treatment group TC, TG, LDL and visfatin express were significantly lower than before treatment (P<0.05, P<0.01), HDL were significantly higher than before treatment (P<0.05). Rosiglitazone group clinical efficient (95.2%) were higher than that control group (P<0.05). The adverse reaction rates of rosiglitazone group (23.8%) and control group (21.4%) showed no significant difference (P>0.05).CONCLUSION: Rosiglitazone treatment showed more effective to reduce the serum level of glucose, lipid and visfatin, with the low rate of adverse reactions.